A Preparation and Evaluation of Sustained Release Tablets of Valacyclovir

Abstract

Valacyclovir HCL is a prodrug of acyclovir that is metabolically activated and inhibits viral DNA replication. It is used to treat and/or prevent certain types of herpes simplex virus (HSV type-1 and HSV type-2) infections, including genital herpes (genital sores) and cold sores (orolabial sores). Valacyclovir is BCS class-III. Drug (high solubility and low permeability). More specifically, it is appreciated that SR formulations are generally designed to release the drug slowly over time and gradually absorb into the upper small intestine. Valacyclovir SR Tablets should be administered twice daily at a dose of 500mg to maintain therapeutically appropriate blood levels of the active ingredient. The aim of the present investigation was to prepare, characterize and evaluate oral sustained release Tablets Valacyclovir to improve adherence and thereby improve efficacy and patient compliance.